RIL
LXEO icon

Rothschild Investment LLC’s Lexeo Therapeutics LXEO Stock Holding History

Rothschild Investment LLC’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$10 – 3649
2025
Q4 		$10 Buy
+1
New +$9 ﹤0.01% 3377
2025
Q1 		– Sell
-20
Closed -$132 – 3071
2024
Q4 		$132 Buy
+20
New +$158 ﹤0.01% 2872

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rothschild Investment LLC's LXEO Position: Q1 2026 in Review

Rothschild Investment LLC sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 1 share — an estimated $10 sold.

Rothschild Investment LLC first reported a position in LXEO in Q4 2024 and held it in 2 quarters. The position peaked at $132 in Q4 2024. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Rothschild Investment LLC reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rothschild Investment LLC sold 1 Lexeo Therapeutics share in Q1 2026, an estimated $10.
  • Rothschild Investment LLC first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 2 quarters.
  • Rothschild Investment LLC's Lexeo Therapeutics position peaked at $132 in Q4 2024.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.